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December 1, 2009:2202–4f the PROSPECT (Predictors of Response to CRT) trial as well as
he role of the sponsor, Medtronic, that require clarification and
orrection. The author claims that study sites were selected solely
ecause they were high-volume cardiac resynchronization therapy
CRT) implantation centers rather than on the basis of echocardio-
raphic experience. The PROSPECT trial included academic and
arge private practice centers in Europe, the U.S., and Hong Kong.
he CRT implantation experience was 1 criterion for selection,
ecause placement of the left ventricular lead is viewed as an
mportant contributor to therapeutic response. Additional and equally
mportant criteria included cooperation among echocardiography,
lectrophysiology, and heart failure specialties within the center; the
bility to collect standard echocardiography data; and a demonstrated
bility to execute clinical trials. Furthermore, sites were accredited by
heir regional core echocardiography laboratory by providing high-
uality images before enrolling subjects (2).
Contrary to Sanderson’s statement (1), enrolling centers were not
equired to analyze tissue Doppler imaging (TDI); this was the
esponsibility of the core echocardiography laboratories (2). Hence,
raining the centers to analyze tissue Doppler images was not
ecessary. The PROSPECT trial was not originally powered to assess
he validity of TDI measures, and as such, sites were not required to
ave echocardiography machines with this capability. During the
tudy but before any analysis, Medtronic supported the physician
teering Committee’s request to expand the enrollment of patients at
enters with TDI-capable equipment, to properly power the study for
nalysis of TDI parameters. Enrollment was increased from an
riginally planned 300 subjects to 498. The Steering Committee—
omprising prominent echocardiographers, heart failure specialists,
nd electrophysiologists—was involved in the trial design and the
ollection, monitoring, and analysis of data (3). Throughout the
xecution of the trial, the sponsor followed their recommendations,
hich included a quality control initiative to ensure consistent
easurements of images by the core laboratories (2).
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eply
thank Dr. Schaber for his clarifications and comments on my
ommentary (1). I have no doubt that the PROSPECT (Predictors of
3esponse to CRT) trial was designed with the best of intentions, but
ometimes there are unforeseen and unintended consequences of
linical trials. The importance of centers having implantation experi-
nce is clearly a sine qua non, but my point was that the echocardi-
graphy experience at these centers might not have been so critically
valuated. This is illustrated by Dr. Schaber’s statement that “enroll-
ng centers were not required to analyze tissue Doppler imaging
TDI); this was the responsibility of the core echocardiography
aboratories. . .hence, training the centers to analyze tissue Doppler
mages was not necessary.” This might be strictly true, but technical
kill is required for the acquisition of the TDI images as well as
nalysis. It is clear from the study design report (2) that TDI
easurements were a critical part of the study from the start (see
able 1 of the article, which lists all the standard and TDI indexes to
e tested). In addition, it was intended that these would be a major
art of the study: page 601: “We will test each echocardiographic
redictor against predetermined primary and secondary response
utcome measures, each with predefined cutoff values.” In light of
his, it is surprising that Dr. Schaber states “The PROSPECT trial
as not originally powered to assess the validity of TDI measure, and
s such, sites were not required to have echocardiography machines
ith this capability.” Indeed, one of the problems in retrospect was the
ack of power. A large number of echocardiographic predictors were
valuated, but individual sample sizes were not calculated; rather,
ower calculations were done on an initial sample size of 250 patients,
ut there is no justification of how this number was decided upon.
urthermore, if there is wide variation in the ability to acquire
igh-quality images, then analysis will be difficult no matter how good
he training is, and this will affect the power of the study—as
ubsequently became obvious in the published results (3). For exam-
le, even the results of the relatively simple measurement of left
entricular volume were often widely different in the implanting
enters compared with the core laboratories, as I pointed out in my
ommentary. Thus, a potentially useful tool has been discredited and
ow practically all but discarded, which might not be in the best
nterest of potential patients or the community paying for the excess
umber of implanted devices.
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